FastForward Inn Ltd

Investment in Medical Cannabis Company

RNS Number : 2753P
FastForward Innovations Limited
16 February 2021
 

FastForward Innovations Ltd / AIM: FFWD / Sector: Closed End Investments

16 February 2021

FastForward Innovations Ltd ("FastForward" or, "FFWD")

 

Investment in Medical Cannabis Company Kanabo Group Plc

 

FastForward Innovations Ltd, the AIM quoted company focusing on making investments in fast growing and industry leading businesses, is pleased to announce that it has invested £62,500 as part of a £6 million oversubscribed placing at a price of 6.5 pence undertaken by Kanabo Group Plc ('Kanabo'). Kanabo commenced trading on the London Stock Exchange today (LSE: KNB), 16 February 2021, following a reverse takeover of Spinnaker Opportunities Plc.

 

Highlights

· Investment further develops FFWD's exposure to the medicinal cannabis industry

· Kanabo has the only medically-approved vaporisation device, the VapePod®, which provides metered dosages of its proprietary cannabis-based oil formulations

· Kanabo is already engaged in selling its products as part of a Pilot Scheme and expects to soon be ready to scale up its sales

· Strong support seen for Kanabo in £6 million oversubscribed placing

 

 

Ed McDermott, CEO of FastForward, commented: " 'We are delighted to see another cannabis focussed company listing here in London and, although we are disappointed to have been heavily scaled back in the oversubscribed placing, we are pleased to see Kanabo shares having a strong market debut and look forward to further progress."

 

DETAILS

Investment

Kanabo has raised a total of £6 million by way of a placing of 92,307,693 placing and subscription shares ('New Shares') at a price of 6.5 pence ('Issue Price') per New Share. The funds raised through the placing will be used for sales & marketing and research & development.

 

Following admission to trading, FFWD will have a holding of 961,538 ordinary shares in Kanabo representing 0.27 per cent of the issued share capital of Kanabo.  The market capitalisation of Kanabo on Admission at the Issue Price was approximately £23.4 million. On its first day of trading, the shares are trading at a significant premium to the Issue Price. 

 

About Kanabo

Kanabo is aiming to create a new standard in the medical cannabis industry to improve the well-being of millions around the world. Kanabo will focus on the distribution of cannabis-derived products for medical patients, and THC-free CBD products for consumers. Kanabo has conducted extensive research and development at its research centre in Israel to develop high-quality Cannabis extract formulas, innovative medical-grade vaporisers, and various non-smoking consumption solutions, making it easy and accessible for anyone in need of treatment. Kanabo has the only medically-approved vaporisation device, the VapePod®, which provides metered dosages of its proprietary cannabis-based oil formulations and is engaged in selling its products as part of a Pilot Scheme and expects to soon be ready to scale up its sales.

 

Further information about Kanabo Group Plc can be found at www.kanabogroup.com .  

 

ENDS

 

For further information on the Company please visit www.fstfwd.co   or contact:

Ed McDermott

Lance de Jersey

FastForward Innovations Ltd

E: [email protected]  

 

James Biddle

Roland Cornish

Beaumont Cornish Limited,

Nomad

T: (0)20 7628 3396

 

Isabella Pierre

Damon Heath

Shard Capital Partners LLP

Broker

T: (0)20 7186 9927

Catherine Leftley

Beth Melluish

St Brides Partners Ltd,

Financial PR

E: [email protected]

 

Notes

FastForward Innovations is an AIM quoted investment company focused primarily on disruptive high growth life sciences and technology businesses particularly within the medical cannabis arena. The Company's strategy is to identify early-stage opportunities that have an upcoming investment catalyst and grow its portfolio in terms of value whilst limiting the number of investee companies to a level where relevant time can be devoted to each.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCMZGMZZVRGMZM